vs
BioRestorative Therapies, Inc.（BRTX）与CRYO CELL INTERNATIONAL INC（CCEL）财务数据对比。点击上方公司名可切换其他公司
CRYO CELL INTERNATIONAL INC的季度营收约是BioRestorative Therapies, Inc.的400.2倍（$7.8M vs $19.6K）。CRYO CELL INTERNATIONAL INC净利率更高（-48.7% vs -16365.5%，领先16316.8%）。CRYO CELL INTERNATIONAL INC同比增速更快（-2.3% vs -54.7%）。CRYO CELL INTERNATIONAL INC自由现金流更多（$1.2M vs $-2.5M）。过去两年CRYO CELL INTERNATIONAL INC的营收复合增速更高（-0.1% vs -25.2%）
BioRestorative Therapies, Inc.是一家临床阶段生物技术企业，专注于创新再生医学疗法的研发，核心管线覆盖慢性腰痛、代谢类疾病等未被满足的医疗需求领域，主要面向北美市场，推进细胞类创新候选治疗产品的临床开发工作。
Cryo-Cell国际是一家脐带血库企业，由丹·理查德于1989年创立，是全球首家分离并储存干细胞的民营脐带血库，总部位于佛罗里达州奥兹马尔，地处坦帕市郊。
BRTX vs CCEL — 直观对比
营收规模更大
CCEL
是对方的400.2倍
$19.6K
营收增速更快
CCEL
高出52.5%
-54.7%
净利率更高
CCEL
高出16316.8%
-16365.5%
自由现金流更多
CCEL
多$3.7M
$-2.5M
两年增速更快
CCEL
近两年复合增速
-25.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6K | $7.8M |
| 净利润 | $-3.2M | $-3.8M |
| 毛利率 | 91.7% | 77.9% |
| 营业利润率 | -19516.8% | -50.6% |
| 净利率 | -16365.5% | -48.7% |
| 营收同比 | -54.7% | -2.3% |
| 净利润同比 | -96.0% | -105.1% |
| 每股收益（稀释后） | $-0.31 | $-0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BRTXCCEL
| Q4 25 | $19.6K | $7.8M | ||
| Q3 25 | $11.8K | $7.8M | ||
| Q2 25 | $303.3K | $7.9M | ||
| Q1 25 | $25.0K | $8.0M | ||
| Q4 24 | $43.3K | $8.0M | ||
| Q3 24 | $233.6K | $8.1M | ||
| Q2 24 | $89.1K | $8.0M | ||
| Q1 24 | $35.0K | $7.9M |
净利润BRTXCCEL
| Q4 25 | $-3.2M | $-3.8M | ||
| Q3 25 | $-3.0M | $749.4K | ||
| Q2 25 | $-2.7M | $355.8K | ||
| Q1 25 | $-5.3M | $282.9K | ||
| Q4 24 | $-1.6M | $-1.9M | ||
| Q3 24 | $-1.1M | $1.1M | ||
| Q2 24 | $-4.0M | $655.8K | ||
| Q1 24 | $-2.2M | $556.2K |
毛利率BRTXCCEL
| Q4 25 | 91.7% | 77.9% | ||
| Q3 25 | 10.4% | 77.0% | ||
| Q2 25 | 97.1% | 76.6% | ||
| Q1 25 | 88.4% | 75.1% | ||
| Q4 24 | 92.3% | 78.4% | ||
| Q3 24 | 92.2% | 73.6% | ||
| Q2 24 | 92.7% | 74.8% | ||
| Q1 24 | 100.0% | 73.7% |
营业利润率BRTXCCEL
| Q4 25 | -19516.8% | -50.6% | ||
| Q3 25 | -31432.3% | 24.3% | ||
| Q2 25 | -1089.8% | 18.8% | ||
| Q1 25 | -19230.1% | 13.3% | ||
| Q4 24 | -6212.8% | -1.5% | ||
| Q3 24 | -979.0% | 17.2% | ||
| Q2 24 | -2770.8% | 17.3% | ||
| Q1 24 | -11740.7% | 10.5% |
净利率BRTXCCEL
| Q4 25 | -16365.5% | -48.7% | ||
| Q3 25 | -25748.1% | 9.6% | ||
| Q2 25 | -875.8% | 4.5% | ||
| Q1 25 | -21359.2% | 3.5% | ||
| Q4 24 | -3778.6% | -23.2% | ||
| Q3 24 | -467.2% | 13.0% | ||
| Q2 24 | -4521.4% | 8.2% | ||
| Q1 24 | -6352.2% | 7.1% |
每股收益（稀释后）BRTXCCEL
| Q4 25 | $-0.31 | $-0.46 | ||
| Q3 25 | $-0.33 | $0.09 | ||
| Q2 25 | $-0.30 | $0.04 | ||
| Q1 25 | $-0.64 | $0.03 | ||
| Q4 24 | $-0.20 | $-0.23 | ||
| Q3 24 | $-0.13 | $0.13 | ||
| Q2 24 | $-0.50 | $0.08 | ||
| Q1 24 | $-0.33 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0M | $3.3M |
| 总债务越低越好 | — | $8.4M |
| 股东权益账面价值 | $356.7K | $-18.6M |
| 总资产 | $4.1M | $61.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BRTXCCEL
| Q4 25 | $3.0M | $3.3M | ||
| Q3 25 | $4.5M | $3.2M | ||
| Q2 25 | $7.4M | $4.4M | ||
| Q1 25 | $9.1M | $3.5M | ||
| Q4 24 | $10.7M | $3.5M | ||
| Q3 24 | $13.1M | $2.1M | ||
| Q2 24 | $14.7M | $1.5M | ||
| Q1 24 | $16.4M | $979.6K |
总债务BRTXCCEL
| Q4 25 | — | $8.4M | ||
| Q3 25 | — | $8.4M | ||
| Q2 25 | — | $8.4M | ||
| Q1 25 | — | $8.5M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | — | $8.5M | ||
| Q2 24 | — | $8.5M | ||
| Q1 24 | — | $8.6M |
股东权益BRTXCCEL
| Q4 25 | $356.7K | $-18.6M | ||
| Q3 25 | $2.2M | $-14.8M | ||
| Q2 25 | $4.8M | $-15.6M | ||
| Q1 25 | $6.1M | $-14.7M | ||
| Q4 24 | $8.5M | $-13.2M | ||
| Q3 24 | $10.0M | $-9.6M | ||
| Q2 24 | $10.8M | $-10.7M | ||
| Q1 24 | $14.5M | $-10.3M |
总资产BRTXCCEL
| Q4 25 | $4.1M | $61.7M | ||
| Q3 25 | $5.6M | $63.2M | ||
| Q2 25 | $8.5M | $64.4M | ||
| Q1 25 | $10.3M | $64.4M | ||
| Q4 24 | $12.3M | $64.7M | ||
| Q3 24 | $14.6M | $62.9M | ||
| Q2 24 | $16.1M | $62.6M | ||
| Q1 24 | $18.0M | $61.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.4M | $1.3M |
| 自由现金流经营现金流 - 资本支出 | $-2.5M | $1.2M |
| 自由现金流率自由现金流/营收 | -12728.8% | 15.5% |
| 资本支出强度资本支出/营收 | 406.5% | 0.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $5.2M |
8季度趋势，按日历期对齐
经营现金流BRTXCCEL
| Q4 25 | $-2.4M | $1.3M | ||
| Q3 25 | $-2.9M | $2.5M | ||
| Q2 25 | $-2.7M | $707.0K | ||
| Q1 25 | $-2.8M | $954.1K | ||
| Q4 24 | $-2.3M | $2.2M | ||
| Q3 24 | $-1.7M | $2.4M | ||
| Q2 24 | $-1.9M | $1.8M | ||
| Q1 24 | $-2.3M | $-356.9K |
自由现金流BRTXCCEL
| Q4 25 | $-2.5M | $1.2M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | — | $644.6K | ||
| Q1 25 | $-2.8M | $892.0K | ||
| Q4 24 | — | $2.1M | ||
| Q3 24 | $-1.8M | $2.3M | ||
| Q2 24 | — | $21.5K | ||
| Q1 24 | — | $-814.6K |
自由现金流率BRTXCCEL
| Q4 25 | -12728.8% | 15.5% | ||
| Q3 25 | — | 31.9% | ||
| Q2 25 | — | 8.1% | ||
| Q1 25 | -11260.7% | 11.2% | ||
| Q4 24 | — | 26.8% | ||
| Q3 24 | -752.6% | 27.9% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | -10.4% |
资本支出强度BRTXCCEL
| Q4 25 | 406.5% | 0.9% | ||
| Q3 25 | 0.0% | 0.5% | ||
| Q2 25 | 0.0% | 0.8% | ||
| Q1 25 | 145.6% | 0.8% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | 25.0% | 2.3% | ||
| Q2 24 | — | 21.8% | ||
| Q1 24 | — | 5.8% |
现金转化率BRTXCCEL
| Q4 25 | — | — | ||
| Q3 25 | — | 3.38× | ||
| Q2 25 | — | 1.99× | ||
| Q1 25 | — | 3.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.32× | ||
| Q2 24 | — | 2.70× | ||
| Q1 24 | — | -0.64× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
